共 11 条
- [9] Ipilimumab plus nivolumab for advanced melanoma [J]. LANCET ONCOLOGY, 2016, 17 (11): : 1471 - 1472
- [10] Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of Interferon- alpha-2b (IFN) with observation: ulceration of primary is key determinant for IFN- sensitivity.[J] . Alexander M.M. Eggermont,Stefan Suciu,Piotr Rutkowski,Willem H. Kruit,Cornelis J. Punt,Reinhard Dummer,Fran?ois Salès,Ulrich Keilholz,Gaetan de Schaetzen,Alessandro Testori. European Journal of Cancer . 2015